Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy-Reference-Cited by-同舟云学术

Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

Published:2021-06 Issue: Volume:150 Page:224-231
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Buti Sebastiano^ORCID,Bersanelli Melissa^ORCID,Perrone Fabiana^ORCID,Bracarda Sergio,Di Maio Massimo,Giusti Raffaele,Nigro Olga,Cortinovis Diego L.^ORCID,Aerts Joachim G.J.V.,Guaitoli Giorgia,Barbieri Fausto^ORCID,Ferrara Miriam G.^ORCID,Bria Emilio^ORCID,Grossi Francesco,Bareggi Claudia,Berardi Rossana,Torniai Mariangela,Cantini Luca^ORCID,Sforza Vincenzo,Genova Carlo,Chiari Rita,Rocco Danilo^ORCID,Della Gravara Luigi^ORCID,Gori Stefania,De Tursi Michele,Di Marino Pietro,Mansueto Giovanni,Zoratto Federica,Filetti Marco,Citarella Fabrizio^ORCID,Russano Marco,Mazzoni Francesca,Garassino Marina C.,De Toma Alessandro,Signorelli Diego,Gelibter Alain,Siringo Marco,Follador Alessandro,Bisonni Renato,Tuzi Alessandro,Minuti Gabriele,Landi Lorenza,Ricciardi Serena^ORCID,Migliorino Maria R.,Tabbò Fabrizio,Olmetto Emanuela,Metro Giulio,Adamo Vincenzo,Russo Alessandro,Spinelli Gian P.,Banna Giuseppe L.,Addeo Alfredo^ORCID,Friedlaender Alex,Cannita Katia,Porzio Giampiero,Ficorella Corrado,Carmisciano Luca^ORCID,Pinato David J.,Mazzaschi Giulia,Tiseo Marcello,Cortellini Alessio

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Association of sex, age, and eastern cooperative Oncology group performance status with survival benefit of cancer immunotherapy in randomized clinical trials: a systematic review and meta-analysis;Yang;JAMA Netw Open,2020

2. Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis;El-Osta;Immunotherapy,2019

3. A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer;Chiu;Transl Lung Cancer Res,2020

4. The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer;Ichihara;Lung Canc,2020

5. The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors;Perrone;J Immunother,2020

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis;Journal for ImmunoTherapy of Cancer;2024-03

2. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18

3. PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC patients treated with PD-L1 inhibitors;BMC Pulmonary Medicine;2023-11-11

4. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study;Cancer Immunology, Immunotherapy;2023-09-07

5. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study;CANCER IMMUNOL IMMUN;2023